Covered recipient · General Payments record
JAMES C HOLLER
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$2,344.76
- Reported across 146 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $306.08 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $84.21 | 5 |
| GlaxoSmithKline, LLC. | $39.00 | 2 |
| PFIZER INC. | $36.26 | 2 |
| Phathom Pharmaceuticals, Inc. | $34.82 | 2 |
| ABBVIE INC. | $34.50 | 1 |
| Acerta Pharma LLC | $32.42 | 2 |
| Abbott Laboratories | $23.93 | 1 |
| Lilly USA, LLC | $20.94 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $23.93 | 07/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124966776 | CMS |
| ABBVIE INC. | $34.50 | 04/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1103931420 | CMS |
| AstraZeneca Pharmaceuticals LP | $19.31 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105201574 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.11 | 04/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104382699 | CMS |
| GlaxoSmithKline, LLC. | $18.47 | 10/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116353714 | CMS |
| GlaxoSmithKline, LLC. | $20.53 | 11/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116302162 | CMS |
| Lilly USA, LLC | $20.94 | 11/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135037181 | CMS |
| Novo Nordisk Inc | $14.56 | 04/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096695778 | CMS |
| Novo Nordisk Inc | $20.13 | 09/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096628209 | CMS |
| Novo Nordisk Inc | $16.35 | 10/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097559669 | CMS |
| Novo Nordisk Inc | $14.78 | 11/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096635754 | CMS |
| Novo Nordisk Inc | $18.39 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097233002 | CMS |
| PFIZER INC. | $17.59 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132090505 | CMS |
| PFIZER INC. | $18.67 | 12/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131158924 | CMS |
| Phathom Pharmaceuticals, Inc. | $17.41 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151072966 | CMS |
| Phathom Pharmaceuticals, Inc. | $17.41 | 05/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151072968 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.